TrialThe lancet. HIV2019

Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial.

Giuseppe Pantaleo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.